Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience

[1]  Jeffrey E. Lee,et al.  Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma , 2016, Cancer.

[2]  L. Schwartz,et al.  Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. , 2016, JAMA surgery.

[3]  D. Bentrem,et al.  A Graded Evaluation of Outcomes Following Pancreaticoduodenectomy with Major Vascular Resection in Pancreatic Cancer , 2016, Journal of Gastrointestinal Surgery.

[4]  Jeffrey E. Lee,et al.  The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy , 2016, Histopathology.

[5]  B. Erickson,et al.  Neoadjuvant therapy for localized pancreatic cancer: guiding principles. , 2015, Journal of gastrointestinal oncology.

[6]  S. Weber,et al.  Has survival following pancreaticoduodenectomy for pancreas adenocarcinoma improved over time? , 2015, Journal of surgical oncology.

[7]  Jeffrey E. Lee,et al.  Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2015, The American journal of surgical pathology.

[8]  J. Boughey,et al.  Improving resection rates in borderline resectable pancreatic cancer: Pilot study shows favorable results. , 2015, Bulletin of the American College of Surgeons.

[9]  Jeffrey E. Lee,et al.  The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy , 2015, Annals of Surgical Oncology.

[10]  A. Ejaz,et al.  Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis , 2015, Annals of Surgical Oncology.

[11]  Douglas B. Evans,et al.  Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy , 2015, Annals of Surgical Oncology.

[12]  S. Maithel,et al.  Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability , 2015, Journal of surgical oncology.

[13]  S. Barni,et al.  FOLFIRINOX-Based Neoadjuvant Therapy in Borderline Resectable or Unresectable Pancreatic Cancer: A Meta-Analytical Review of Published Studies , 2015, Pancreas.

[14]  J. Cameron,et al.  Two thousand consecutive pancreaticoduodenectomies. , 2015, Journal of the American College of Surgeons.

[15]  M. Bloomston,et al.  Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas , 2015, Annals of Surgical Oncology.

[16]  C. Moulton,et al.  Improved Long-Term Outcomes After Resection of Pancreatic Adenocarcinoma: A Comparison Between Two Time Periods , 2015, Annals of Surgical Oncology.

[17]  Jeffrey E. Lee,et al.  Phase II study of preoperation mFOLFIRINOX and chemoradiation for high-risk resectable and borderline resectable pancreatic adenocarcinoma. , 2015 .

[18]  D. Abbott,et al.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. , 2014, World journal of gastroenterology.

[19]  Jeffrey E. Lee,et al.  Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[20]  J. Pickleman,et al.  Clinical and Pathologic Features Influencing Survival in Patients Undergoing Pancreaticoduodenectomy for Pancreatic Adenocarcinoma , 2014, Journal of Gastrointestinal Surgery.

[21]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[22]  Edward J. Kim,et al.  A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer , 2013, Cancer.

[23]  K. Lillemoe,et al.  Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a “True” R0 Resection? , 2013, Annals of surgery.

[24]  Jeffrey E. Lee,et al.  Frequency and Intensity of Postoperative Surveillance After Curative Treatment of Pancreatic Cancer: A Cost-Effectiveness Analysis , 2013, Annals of Surgical Oncology.

[25]  M. Korc,et al.  Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Jeffrey E. Lee,et al.  Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. , 2012, Journal of the American College of Surgeons.

[27]  C. Verbeke,et al.  Resection margin involvement and tumour origin in pancreatic head cancer , 2012, The British journal of surgery.

[28]  Jeffrey E. Lee,et al.  Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma , 2012, Cancer.

[29]  Jeffrey E. Lee,et al.  Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[30]  Jeffrey E. Lee,et al.  Perineural and Intraneural Invasion in Posttherapy Pancreaticoduodenectomy Specimens Predicts Poor Prognosis in Patients With Pancreatic Ductal Adenocarcinoma , 2012, The American journal of surgical pathology.

[31]  Jeffrey E. Lee,et al.  Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy , 2012, Annals of Surgical Oncology.

[32]  M. Gnant,et al.  NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. , 2011, Surgery.

[33]  M. Ychou,et al.  Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[34]  Jeffrey E. Lee,et al.  Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation , 2010, Annals of Surgical Oncology.

[35]  T. Keck,et al.  The Lymph Node Ratio is the Strongest Prognostic Factor after Resection of Pancreatic Cancer , 2009, Journal of Gastrointestinal Surgery.

[36]  Alison P. Klein,et al.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Ychou,et al.  Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma: The French Phase II FFCD 9704-SFRO Trial , 2008, American journal of clinical oncology.

[38]  Jeffrey E. Lee,et al.  Anatomy of the Superior Mesenteric Vein With Special Reference to the Surgical Management of First-order Branch Involvement at Pancreaticoduodenectomy , 2008, Annals of surgery.

[39]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Jeffrey E. Lee,et al.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Jeffrey E. Lee,et al.  Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. , 2008, Journal of the American College of Surgeons.

[42]  Douglas B. Evans,et al.  Development of an Integrated Biospecimen Bank and Multidisciplinary Clinical Database For Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[43]  C. Ko,et al.  Multimodality therapy for pancreatic cancer in the U.S. , 2007, Cancer.

[44]  Jeffrey E. Lee,et al.  Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant therapy? , 2007, Journal of the American College of Surgeons.

[45]  Michael A. Choti,et al.  1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience , 2006, Journal of Gastrointestinal Surgery.

[46]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[47]  T. Kosuge,et al.  A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. , 2006, Japanese journal of clinical oncology.

[48]  Christopher H. Crane,et al.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration , 2004, Journal of Gastrointestinal Surgery.

[49]  Jeffrey E. Lee,et al.  Abstracts reprinted from Journal of Clinical Oncology , 2002, Annals of Surgical Oncology.

[50]  D. Deziel,et al.  Prognostic Factors Associated with Resectable Adenocarcinoma of the Head of the Pancreas , 1999, The American surgeon.

[51]  Jeffrey E. Lee,et al.  Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Goodman,et al.  Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients , 1995, Annals of surgery.

[54]  F. Ames,et al.  Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. , 1992, Archives of surgery.

[55]  M. Pilepich,et al.  Preoperative irradiation in carcinoma of the pancreas , 1980, Cancer.

[56]  P. Mishra,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2015, Annals of surgery.

[57]  Julian A. Kim,et al.  Trends in the Treatment of Resectable Pancreatic Adenocarcinoma , 2013, Journal of Gastrointestinal Surgery.

[58]  Jeffrey E. Lee,et al.  Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival , 2013, Journal of Gastrointestinal Surgery.

[59]  D. Fraker,et al.  A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[60]  K. Behrns.  FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer , 2012 .

[61]  Laura H. Tang,et al.  Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades , 2011, Annals of Surgical Oncology.

[62]  Jeffrey E. Lee,et al.  Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[63]  T. Eberlein.  Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial , 2008 .

[64]  Greco Fa,et al.  Adjuvant Combination Chemotherapy (AMF) Following Radical Resection of Carcinoma of the Pancreas and Papilla of Vater Results of a Controlled, Prospective, Randomised Multicentre Study , 1993 .